New peptides to treat cognitive impairment of age-related diseases

Patent number:

EP25382703

Comunidad de Madrid.svg
No items found.

Novel Folate Receptor alpha (FRα) binding peptides induce brain cell reprograming and rejuvenation, enhancing cognitive function in aged mice. These unique peptides are able to cross the blood-brain barrier and specifically bind to FRα in brain cells.

Countries:
Spain
Regions:
Community of Madrid
Centers:
CSIC, UNIVERSIDAD AUTONOMA DE MADRID
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 4 – technology validated in lab
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
Applications

• Cognitive improvement of recognition and spatial memory. • Specific binding to neuroepithelial FRα, preventing from systemic toxic effect associated to high-doses of folate administration. • Blood-brain barrier permeability, enabling versatile administration routes, including intracranial, peritoneal and intragastric. • Safety and efficacy proven in pre-clinical mouse models.

Comments

Other related patents

Health

COMBINATIONS WITH THIAZOLIDINEDIONES FOR USE IN THE PREVENTION OR TREATMENT OF ABNORMAL BONE GROWTH

Countries
Spain
Know more
Health

METHOD FOR MINIMAL RESIDUAL DISEASE DETECTION IN CANCER PATIENTS

Countries
Spain
Know more
Health

SYSTEM FOR CAPTURING AND INACTIVATING PATHOGENS

Countries
Spain
Know more
Get back to patents directory